PTC Therapeutics
PTCT
125 hedge funds and large institutions have $636M invested in PTC Therapeutics in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 26 closing their positions.
13% more capital inflows, than outflows
Capital inflows: $182M | Capital outflows: $162M
5.48% more ownership
Funds ownership: 86.37% → 91.86% (+5.5%)
2% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 41
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
3% less funds holding
Funds holding: 129 → 125 (-4)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
81% less call options, than puts
Call options by funds: $9.17M | Put options by funds: $48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Scopia Capital Management
New York
|
+$49.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.4M |
| 3 |
RTW Investments
New York
|
+$10.7M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$10.7M |
| 5 |
J. Goldman & Co
New York
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
-$79M |
| 2 |
DLD Asset Management
New York
|
-$12.3M |
| 3 |
Numeric Investors
Boston,
Massachusetts
|
-$9.42M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8M |
| 5 |
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$6.72M |
PTCT Hedge Fund Activity: Q4 2017 in Review
125 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2017, worth a combined $636M — down 11% from $715M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PTCT and 24 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 42 added.
The largest buyer was Scopia Capital Management, adding an estimated $49.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $79M sold.
- 125 institutional investors held PTC Therapeutics (PTCT) as of Q4 2017, down from 129 in Q3 2017.
- Funds reported $636M of PTC Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
- 24 funds opened new PTC Therapeutics positions in Q4 2017 and 26 closed out, a net change of -2 holders.
- The largest PTC Therapeutics buyer in Q4 2017 was Scopia Capital Management, an estimated $49.9M added.
- The largest PTC Therapeutics seller in Q4 2017 was Consonance Capital Management, an estimated $79M sold.
Based on aggregated 13F filings for Q4 2017.